Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

963
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
963
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malignant teratoid medulloepithelioma with retinal invasion masquerading as vasoproliferative retinal tumor in an adult.

American journal of ophthalmology case reports·2026
Same author

Optical Coherence Tomography Features of Retinal Leukemic Infiltrates and Their Association With Visual Prognosis.

Journal of vitreoretinal diseases·2026
Same author

Accuracy of Retinal Pigment Epithelium (RPE) undulations (Oscillatory sign) as an optical coherence tomography biomarker of acute RPE tears.

International journal of retina and vitreous·2026
Same author

Type I to type II Boston keratoprosthesis exchange: a report of two patients.

BMC ophthalmology·2026
Same author

Late Diagnostic Revision to Tubercular Choroiditis in Patients with Recurrent APMPPE: A Retrospective Study in 28 Cases.

Ocular immunology and inflammation·2026
Same author

Effect of Anti-Tubercular Therapy Duration (6 Months versus ≥9-Months) on Treatment Outcomes in Serpiginous-Like Choroiditis: A Multicenter Retrospective Observational Study.

Ocular immunology and inflammation·2026

Related Experiment Video

Updated: Jan 18, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.0K

Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study.

Soumyava Basu1, Sucheta Ireni1, Mudit Tyagi1,2

  • 1Saroja A Rao Center for Uveitis, LV Prasad Eye Institute, Hyderabad, India.

Ocular Immunology and Inflammation
|May 27, 2025
PubMed
Summary

Low-dose subconjunctival adalimumab (5 mg) is safe and effective for non-infectious uveitis (NIU) refractory to conventional therapy. This treatment improved inflammatory scores and visual acuity in patients with persistent intraocular inflammation.

Keywords:
Adalimumabnon-infectiousrefractorysubconjunctivaluveitis

More Related Videos

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.6K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.6K

Related Experiment Videos

Last Updated: Jan 18, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

6.0K
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

3.6K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.6K

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Non-infectious uveitis (NIU) poses a significant challenge, especially when refractory to conventional immunomodulatory therapy (IMT).
  • Persistent intraocular inflammation can lead to vision loss and requires novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with NIU.
  • To assess the impact of subconjunctival adalimumab on inflammatory markers and visual acuity in refractory NIU cases.

Main Methods:

  • A prospective, noncomparative, interventional case series involving five patients with bilateral panuveitis.
  • Patients received three doses of subconjunctival adalimumab (5 mg/0.1 mL) at two-week intervals, with a 24-week follow-up period.

Main Results:

  • No serious adverse events such as conjunctival congestion, corneal issues, or elevated intraocular pressure were reported.
  • Three out of five patients showed improvement in inflammatory scores and best-corrected visual acuity (BCVA).
  • No baseline factors like cystoid macular edema or vitreous haze explained the BCVA improvement in the responding patients.

Conclusions:

  • Subconjunctival administration of 5 mg adalimumab is a safe treatment option for NIU.
  • This method demonstrates preliminary efficacy in managing NIU refractory to conventional IMT.